Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03283085 · ClinicalTrials.gov registry record · Phase 3
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 557
- Enrollment target
NCT03283085 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 557 participants.
The verdict
NCT03283085, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 557 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
Interventions
- DRUG 25 mg Ontamalimab
- DRUG 75 mg Ontamalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2023-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03283085
The ClinicalTrials.gov registry entry for NCT03283085 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 557 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 25 mg Ontamalimab is the first listed.
NCT03283085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03283085 about?
NCT03283085 is a clinical study titled "A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)". The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
What is the current status of trial NCT03283085?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 557 participants. The study started on 2018-02-27. Estimated completion is 2023-12-13.
What interventions are being tested in trial NCT03283085?
The interventions under investigation include: 25 mg Ontamalimab (DRUG), 75 mg Ontamalimab (DRUG).
Who is sponsoring clinical trial NCT03283085?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.